Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | G6PD | P11413 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1983658 | 0.75 | TSHR (0.32) | TP53TSHR | |
| SCHEMBL1028769 | 0.70 | — | — | |
| SCHEMBL15648819 | 0.70 | BDKRB2 (0.36) | ALDH1A1TP53CYP3A4TSHRHSD17B10 | |
| SCHEMBL276811 | 0.70 | LTA4H (0.38) | TP53TSHR | |
| SCHEMBL15648671 | 0.70 | BDKRB2 (0.36) | ALDH1A1TP53CYP3A4TSHRHSD17B10 | |
| SCHEMBL1452840 | 0.68 | HTT (0.38) | ALDH1A1CYP3A4G6PDHPGDTSHR | |
| Hydrogen Sulfide SCHEMBL9374535 | 0.68 | DNM1 (0.37) | TP53TSHR | |
| SCHEMBL5787759 | 0.67 | MAPT (0.41) | DRD3ALDH1A1CYP3A4TSHR | |
| SCHEMBL9901980 | 0.67 | BDKRB2 (0.35) | — | |
| SCHEMBL1096789 | 0.67 | HTR7 (0.41) | HSP90AA1HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119241818-A | Wide-band gap conjugated polymer donor material and preparation method and application thereof | 青岛大学 | 2025-01-03 | — | — | CN | claimed |
| CN-119241818-A | Wide-band gap conjugated polymer donor material and preparation method and application thereof | 青岛大学 | 2025-01-03 | — | — | CN | disclosed |
| EP-1644370-A4 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2008-06-04 | — | — | EP | disclosed |
| EP-1592698-B1 | PHOSPHINE COMPOUND, INTERMEDIATE, PALLADIUM-COMPLEX, AND USE THEREOF | TAKASAGO PERFUMERY CO LTD (JP) | 2008-03-26 | — | — | EP | disclosed |
| US-7276608-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-7144913-B2 | Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists | MERCK FROSST CANADA & CO. (CA) | 2006-12-05 | — | — | US | disclosed |
| US-7129367-B2 | Phosphine compound, its intermediate, its complex with palladium and a manufacturing method of unsaturated compounds by using the palladium complex | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-10-31 | — | — | US | disclosed |
| US-7129253-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1395590-B1 | DIHYDROPYRROLO¬1,2-A|INDOLE AND TETRAHYDROPYRIDO¬1,2-A|INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA INC (CA) | 2006-09-27 | — | — | EP | disclosed |
| US-7105529-B2 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-12 | — | — | US | disclosed |
| EP-0611749-A1 | Substituted amic acid derivatives useful for treatment of arteriosclerosis | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1994-08-24 | — | — | EP | disclosed |
| US-5324721-A | 3-Substituted cephalosporins, and their use as medicaments | BAYER AKTIENGESELLSCHAFT (DE) | 1994-06-28 | — | — | US | disclosed |
| US-5306728-A | Substituted amine derivatives having antihyperlipemia activity | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1994-04-26 | — | — | US | disclosed |
| EP-0587430-A1 | Substituted acetamide derivatives for treatment of hypocholesterolaemia, hyperlipaemia and arteriosclerosis | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1994-03-16 | — | — | EP | disclosed |
| EP-0567469-A1 | 14-g(b)-H-, 14- AND 15-EN-11-g(b)-aryl-4-ESTRENES. | SCHERING AG (DE) | 1993-11-03 | — | — | EP | disclosed |
| US-5234946-A | Anticholesterol, antilipemic | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-08-10 | — | — | US | disclosed |
| CN-1066271-A | 14 β-H-14-and 15-ethylene linkage-11 beta-aryl-4-estrene | SCHERING AG (DE) | 1992-11-18 | — | — | CN | disclosed |
| WO-1992011278-A1 | 14β-H-, 14- AND 15-EN-11β-aryl-4-ESTRENES | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1992-07-09 | — | — | WO | disclosed |
| EP-0448078-A2 | Substituted amine derivatives having anti-hyperlipemia activity | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1991-09-25 | — | — | EP | disclosed |
| EP-0395768-A1 | SUBSTITUTED ALLYLAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1990-11-07 | — | — | EP | disclosed |